Selective PDE inhibitors as novel treatments for respiratory diseases
- PMID: 22497841
- DOI: 10.1016/j.coph.2012.02.016
Selective PDE inhibitors as novel treatments for respiratory diseases
Abstract
Phosphodiesterases (PDEs) are a family of enzymes which catalyse the metabolism of the intracellular cyclic nucleotides, c-AMP and c-GMP that are expressed in a variety of cell types and in the context of respiratory diseases, It is now recognised that the use of PDE3, PDE4 and mixed PDE3/4 inhibitors can provide clinical benefit to patients with asthma or chronic obstructive pulmonary disease (COPD). The orally active PDE4 inhibitor Roflumilast-n-oxide has been approved for treatment of severe exacerbations of COPD as add-on therapy to standard drugs. This review discusses the involvement of PDEs in airway diseases and various strategies that are currently being pursued to improve efficacy and reduce side-effects of PDE4 inhibitors, including delivery via the inhaled route, mixed PDE inhibitors and/or antisense biologicals targeted towards PDE4.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Phosphodiesterase inhibitors in airways disease.Eur J Pharmacol. 2006 Mar 8;533(1-3):110-7. doi: 10.1016/j.ejphar.2005.12.059. Epub 2006 Feb 2. Eur J Pharmacol. 2006. PMID: 16458289 Review.
-
Phosphodiesterase inhibitors in the treatment of inflammatory diseases.Handb Exp Pharmacol. 2011;(204):391-414. doi: 10.1007/978-3-642-17969-3_17. Handb Exp Pharmacol. 2011. PMID: 21695650 Review.
-
Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.Basic Clin Pharmacol Toxicol. 2014 May;114(5):365-76. doi: 10.1111/bcpt.12209. Epub 2014 Mar 6. Basic Clin Pharmacol Toxicol. 2014. PMID: 24517491 Review.
-
Immunological aspects of phosphodiesterase inhibition in the respiratory system.Respir Physiol Neurobiol. 2013 Jun 1;187(1):11-7. doi: 10.1016/j.resp.2013.02.004. Epub 2013 Feb 13. Respir Physiol Neurobiol. 2013. PMID: 23415692 Review.
-
Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors.Curr Opin Pharmacol. 2005 Jun;5(3):238-44. doi: 10.1016/j.coph.2005.04.001. Curr Opin Pharmacol. 2005. PMID: 15907909 Review.
Cited by
-
Administration of Liposomal-Based Pde3b Gene Therapy Protects Mice Against Collagen-Induced Rheumatoid Arthritis via Modulating Macrophage Polarization.Int J Nanomedicine. 2024 May 17;19:4411-4427. doi: 10.2147/IJN.S454445. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38774028 Free PMC article.
-
Possible modulating functions of probiotic Lactiplantibacillus plantarum in particulate matter-associated pulmonary inflammation.Front Cell Infect Microbiol. 2024 Jan 9;13:1290914. doi: 10.3389/fcimb.2023.1290914. eCollection 2023. Front Cell Infect Microbiol. 2024. PMID: 38264731 Free PMC article. Review.
-
Tanshinone IIA protects against chronic obstructive pulmonary disease via exosome‑shuttled miR‑486‑5p.Int J Mol Med. 2022 Jul;50(1):97. doi: 10.3892/ijmm.2022.5153. Epub 2022 May 27. Int J Mol Med. 2022. PMID: 35621142 Free PMC article.
-
An inhibitor of RORγ for chronic pulmonary obstructive disease treatment.Sci Rep. 2022 May 24;12(1):8744. doi: 10.1038/s41598-022-12251-z. Sci Rep. 2022. PMID: 35610240 Free PMC article.
-
Control of the Hedgehog pathway by compartmentalized PKA in the primary cilium.Sci China Life Sci. 2022 Mar;65(3):500-514. doi: 10.1007/s11427-021-1975-9. Epub 2021 Sep 7. Sci China Life Sci. 2022. PMID: 34505970 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical